ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2565

Assessing Participation in the Lupus Sister Circle Support Group

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 1898

Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1966

Assessing the Impact of Cutaneous Melanin on Microvascular Oxygenation Measurement in Systemic Sclerosis Using Multispectral Imaging

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2547

Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2271

Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1895

Assessing the Validity of Self-Reported Medication Data Through Metabolite Analysis: Data from the Osteoarthritis Initiative

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2262

Assessment of small airway disease in rheumatoid arthritis

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2252

Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2366

Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2079

Association Between Symptomatic Knee Osteoarthritis and Health-Related Quality of Life in Individuals with Type 2 Diabetes: A Cross-Sectional Study

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2093

Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-Matched Retrospective Cohort Analysis

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2254

Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2325

Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2286

Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2092

Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study

(2079–2105) Osteoarthritis – Clinical Poster II

«Previous Page
1
…
4
5
6
7
8
…
63
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].